Status:
COMPLETED
Biologic Treatment Registry Across Canada
Lead Sponsor:
Janssen Inc.
Conditions:
Arthritis, Rheumatoid
Spondyloarthritis, Axial
Eligibility:
All Genders
18+ years
Brief Summary
This registry is a multi-center, prospective, longitudinal, observational program that will gather and analyse data on participants treated with infliximab, golimumab, golimumab Intravenous (I.V) or u...
Detailed Description
Participants will be selected for this registry using a non-probability sampling method.
Eligibility Criteria
Inclusion
- Participant is starting infliximab, golimumab, golimumab Intravenous (I.V) or ustekinumab at the time of enrollment and is biologic naive or has been treated with only one prior biologic (including infliximab, golimumab, golimumab I.V or ustekinumab) prior to enrollment
- Participant has signed the approved informed consent form
- Participant is diagnosed with RA, AxSpA or PsA and is eligible for treatment with infliximab, golimumab, golimumab I.V or ustekinumab in accordance with routine clinical care and the Canadian Product Monograph.
Exclusion
- \- Participant was treated with two or more biologics, for any period of time before enrollment
Key Trial Info
Start Date :
February 12 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 29 2018
Estimated Enrollment :
2821 Patients enrolled
Trial Details
Trial ID
NCT00741793
Start Date
February 12 2002
End Date
June 29 2018
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montreal, Quebec, Canada